nodes	percent_of_prediction	percent_of_DWPC	metapath
Arformoterol—Isoprenaline—MAPK1—melanoma	0.00984	1	CrCbGaD
Arformoterol—Dysgeusia—Vemurafenib—melanoma	0.00419	0.00529	CcSEcCtD
Arformoterol—Back pain—Vemurafenib—melanoma	0.00414	0.00522	CcSEcCtD
Arformoterol—Gastroenteritis—Temozolomide—melanoma	0.0041	0.00517	CcSEcCtD
Arformoterol—Injury—Carmustine—melanoma	0.00409	0.00516	CcSEcCtD
Arformoterol—Nasal congestion—Temozolomide—melanoma	0.00398	0.00503	CcSEcCtD
Arformoterol—Cough—Vemurafenib—melanoma	0.00373	0.00471	CcSEcCtD
Arformoterol—Bone disorder—Docetaxel—melanoma	0.00368	0.00465	CcSEcCtD
Arformoterol—Bronchospasm—Bleomycin—melanoma	0.00366	0.00462	CcSEcCtD
Arformoterol—Arthralgia—Vemurafenib—melanoma	0.00364	0.0046	CcSEcCtD
Arformoterol—Myalgia—Vemurafenib—melanoma	0.00364	0.0046	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00362	0.00456	CcSEcCtD
Arformoterol—Anaphylactic shock—Vemurafenib—melanoma	0.00349	0.00441	CcSEcCtD
Arformoterol—Infection—Vemurafenib—melanoma	0.00347	0.00438	CcSEcCtD
Arformoterol—Inflammation—Docetaxel—melanoma	0.00343	0.00433	CcSEcCtD
Arformoterol—Nervous system disorder—Vemurafenib—melanoma	0.00342	0.00432	CcSEcCtD
Arformoterol—Hypokalaemia—Carmustine—melanoma	0.00342	0.00431	CcSEcCtD
Arformoterol—Skin disorder—Vemurafenib—melanoma	0.00339	0.00428	CcSEcCtD
Arformoterol—Dehydration—Temozolomide—melanoma	0.00338	0.00426	CcSEcCtD
Arformoterol—Dry skin—Temozolomide—melanoma	0.00333	0.0042	CcSEcCtD
Arformoterol—Blood pressure increased—Docetaxel—melanoma	0.00333	0.0042	CcSEcCtD
Arformoterol—Hypokalaemia—Temozolomide—melanoma	0.0033	0.00417	CcSEcCtD
Arformoterol—Acute coronary syndrome—Bleomycin—melanoma	0.00327	0.00413	CcSEcCtD
Arformoterol—Hypotension—Vemurafenib—melanoma	0.00326	0.00412	CcSEcCtD
Arformoterol—Myocardial infarction—Bleomycin—melanoma	0.00325	0.0041	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00318	0.00401	CcSEcCtD
Arformoterol—Candida infection—Docetaxel—melanoma	0.00317	0.00401	CcSEcCtD
Arformoterol—Haematuria—Bleomycin—melanoma	0.00316	0.00399	CcSEcCtD
Arformoterol—Bronchitis—Temozolomide—melanoma	0.00302	0.00381	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Vemurafenib—melanoma	0.00301	0.0038	CcSEcCtD
Arformoterol—Fatigue—Vemurafenib—melanoma	0.00301	0.0038	CcSEcCtD
Arformoterol—Neoplasm—Docetaxel—melanoma	0.00301	0.00379	CcSEcCtD
Arformoterol—Constipation—Vemurafenib—melanoma	0.00299	0.00377	CcSEcCtD
Arformoterol—Hyperglycaemia—Carmustine—melanoma	0.00293	0.0037	CcSEcCtD
Arformoterol—Upper respiratory tract infection—Temozolomide—melanoma	0.00292	0.00368	CcSEcCtD
Arformoterol—Hyperglycaemia—Temozolomide—melanoma	0.00283	0.00357	CcSEcCtD
Arformoterol—Urinary tract infection—Carmustine—melanoma	0.00281	0.00355	CcSEcCtD
Arformoterol—Body temperature increased—Vemurafenib—melanoma	0.00276	0.00348	CcSEcCtD
Arformoterol—Pharyngitis—Dactinomycin—melanoma	0.00276	0.00348	CcSEcCtD
Arformoterol—Urinary tract infection—Temozolomide—melanoma	0.00272	0.00343	CcSEcCtD
Arformoterol—Cardiac failure congestive—Docetaxel—melanoma	0.00266	0.00336	CcSEcCtD
Arformoterol—Sinusitis—Temozolomide—melanoma	0.00262	0.00331	CcSEcCtD
Arformoterol—Hypersensitivity—Vemurafenib—melanoma	0.00257	0.00325	CcSEcCtD
Arformoterol—Oedema peripheral—Carmustine—melanoma	0.00256	0.00323	CcSEcCtD
Arformoterol—Connective tissue disorder—Carmustine—melanoma	0.00255	0.00322	CcSEcCtD
Arformoterol—Atrial fibrillation—Docetaxel—melanoma	0.00255	0.00321	CcSEcCtD
Arformoterol—Asthenia—Vemurafenib—melanoma	0.0025	0.00316	CcSEcCtD
Arformoterol—Visual impairment—Carmustine—melanoma	0.0025	0.00316	CcSEcCtD
Arformoterol—Pharyngitis—Temozolomide—melanoma	0.00249	0.00315	CcSEcCtD
Arformoterol—Urinary tract disorder—Temozolomide—melanoma	0.00248	0.00313	CcSEcCtD
Arformoterol—Oedema peripheral—Temozolomide—melanoma	0.00247	0.00312	CcSEcCtD
Arformoterol—Pruritus—Vemurafenib—melanoma	0.00247	0.00312	CcSEcCtD
Arformoterol—Connective tissue disorder—Temozolomide—melanoma	0.00247	0.00311	CcSEcCtD
Arformoterol—Urethral disorder—Temozolomide—melanoma	0.00246	0.00311	CcSEcCtD
Arformoterol—Visual impairment—Temozolomide—melanoma	0.00242	0.00305	CcSEcCtD
Arformoterol—Ill-defined disorder—Bleomycin—melanoma	0.0024	0.00303	CcSEcCtD
Arformoterol—Diarrhoea—Vemurafenib—melanoma	0.00239	0.00301	CcSEcCtD
Arformoterol—Malaise—Bleomycin—melanoma	0.00234	0.00295	CcSEcCtD
Arformoterol—Cardiac disorder—Temozolomide—melanoma	0.00233	0.00294	CcSEcCtD
Arformoterol—Arrhythmia—Carmustine—melanoma	0.00232	0.00293	CcSEcCtD
Arformoterol—Dizziness—Vemurafenib—melanoma	0.00231	0.00291	CcSEcCtD
Arformoterol—Mental disorder—Carmustine—melanoma	0.00228	0.00287	CcSEcCtD
Arformoterol—Immune system disorder—Temozolomide—melanoma	0.00227	0.00286	CcSEcCtD
Arformoterol—Mediastinal disorder—Temozolomide—melanoma	0.00226	0.00286	CcSEcCtD
Arformoterol—Malnutrition—Carmustine—melanoma	0.00226	0.00285	CcSEcCtD
Arformoterol—Cough—Bleomycin—melanoma	0.00226	0.00285	CcSEcCtD
Arformoterol—Dehydration—Docetaxel—melanoma	0.00224	0.00283	CcSEcCtD
Arformoterol—Ill-defined disorder—Dactinomycin—melanoma	0.00224	0.00283	CcSEcCtD
Arformoterol—Vomiting—Vemurafenib—melanoma	0.00222	0.0028	CcSEcCtD
Arformoterol—Dry skin—Docetaxel—melanoma	0.00221	0.00279	CcSEcCtD
Arformoterol—Chest pain—Bleomycin—melanoma	0.00221	0.00278	CcSEcCtD
Arformoterol—Myalgia—Bleomycin—melanoma	0.00221	0.00278	CcSEcCtD
Arformoterol—Rash—Vemurafenib—melanoma	0.0022	0.00278	CcSEcCtD
Arformoterol—Mental disorder—Temozolomide—melanoma	0.0022	0.00278	CcSEcCtD
Arformoterol—Dermatitis—Vemurafenib—melanoma	0.0022	0.00278	CcSEcCtD
Arformoterol—Back pain—Carmustine—melanoma	0.00219	0.00276	CcSEcCtD
Arformoterol—Headache—Vemurafenib—melanoma	0.00219	0.00276	CcSEcCtD
Arformoterol—Malnutrition—Temozolomide—melanoma	0.00219	0.00276	CcSEcCtD
Arformoterol—Discomfort—Bleomycin—melanoma	0.00218	0.00275	CcSEcCtD
Arformoterol—Malaise—Dactinomycin—melanoma	0.00218	0.00275	CcSEcCtD
Arformoterol—Cramp muscle—Docetaxel—melanoma	0.00217	0.00274	CcSEcCtD
Arformoterol—Nasopharyngitis—Docetaxel—melanoma	0.00216	0.00272	CcSEcCtD
Arformoterol—Dysgeusia—Temozolomide—melanoma	0.00214	0.0027	CcSEcCtD
Arformoterol—Tremor—Carmustine—melanoma	0.00212	0.00267	CcSEcCtD
Arformoterol—Anaphylactic shock—Bleomycin—melanoma	0.00212	0.00267	CcSEcCtD
Arformoterol—Oedema—Bleomycin—melanoma	0.00212	0.00267	CcSEcCtD
Arformoterol—Back pain—Temozolomide—melanoma	0.00211	0.00267	CcSEcCtD
Arformoterol—Infection—Bleomycin—melanoma	0.0021	0.00265	CcSEcCtD
Arformoterol—Agitation—Carmustine—melanoma	0.00208	0.00262	CcSEcCtD
Arformoterol—Nausea—Vemurafenib—melanoma	0.00207	0.00262	CcSEcCtD
Arformoterol—Myalgia—Dactinomycin—melanoma	0.00206	0.0026	CcSEcCtD
Arformoterol—Bronchospasm—Docetaxel—melanoma	0.00205	0.00259	CcSEcCtD
Arformoterol—Tremor—Temozolomide—melanoma	0.00205	0.00258	CcSEcCtD
Arformoterol—Discomfort—Dactinomycin—melanoma	0.00203	0.00257	CcSEcCtD
Arformoterol—Angina pectoris—Docetaxel—melanoma	0.00203	0.00256	CcSEcCtD
Arformoterol—Ill-defined disorder—Temozolomide—melanoma	0.00203	0.00256	CcSEcCtD
Arformoterol—Agitation—Temozolomide—melanoma	0.00201	0.00254	CcSEcCtD
Arformoterol—Angioedema—Temozolomide—melanoma	0.002	0.00252	CcSEcCtD
Arformoterol—Hypotension—Bleomycin—melanoma	0.00198	0.00249	CcSEcCtD
Arformoterol—Oedema—Dactinomycin—melanoma	0.00197	0.00249	CcSEcCtD
Arformoterol—Malaise—Temozolomide—melanoma	0.00197	0.00249	CcSEcCtD
Arformoterol—Infection—Dactinomycin—melanoma	0.00196	0.00247	CcSEcCtD
Arformoterol—Hypertension—Carmustine—melanoma	0.00195	0.00246	CcSEcCtD
Arformoterol—Palpitations—Temozolomide—melanoma	0.00193	0.00244	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Bleomycin—melanoma	0.00193	0.00243	CcSEcCtD
Arformoterol—Chest pain—Carmustine—melanoma	0.00193	0.00243	CcSEcCtD
Arformoterol—Myalgia—Carmustine—melanoma	0.00193	0.00243	CcSEcCtD
Arformoterol—Anxiety—Carmustine—melanoma	0.00192	0.00242	CcSEcCtD
Arformoterol—Cough—Temozolomide—melanoma	0.00191	0.00241	CcSEcCtD
Arformoterol—Hypertension—Temozolomide—melanoma	0.00189	0.00238	CcSEcCtD
Arformoterol—Dyspnoea—Bleomycin—melanoma	0.00189	0.00238	CcSEcCtD
Arformoterol—Arthralgia—Temozolomide—melanoma	0.00186	0.00235	CcSEcCtD
Arformoterol—Myalgia—Temozolomide—melanoma	0.00186	0.00235	CcSEcCtD
Arformoterol—Anxiety—Temozolomide—melanoma	0.00185	0.00234	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00185	0.00233	CcSEcCtD
Arformoterol—Oedema—Carmustine—melanoma	0.00185	0.00233	CcSEcCtD
Arformoterol—Discomfort—Temozolomide—melanoma	0.00184	0.00232	CcSEcCtD
Arformoterol—Infection—Carmustine—melanoma	0.00183	0.00231	CcSEcCtD
Arformoterol—Acute coronary syndrome—Docetaxel—melanoma	0.00183	0.00231	CcSEcCtD
Arformoterol—Myocardial infarction—Docetaxel—melanoma	0.00182	0.0023	CcSEcCtD
Arformoterol—Dry mouth—Temozolomide—melanoma	0.00182	0.0023	CcSEcCtD
Arformoterol—Pain—Bleomycin—melanoma	0.00181	0.00228	CcSEcCtD
Arformoterol—Conjunctivitis—Docetaxel—melanoma	0.00181	0.00228	CcSEcCtD
Arformoterol—Tachycardia—Carmustine—melanoma	0.0018	0.00227	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Dactinomycin—melanoma	0.0018	0.00227	CcSEcCtD
Arformoterol—Anaphylactic shock—Temozolomide—melanoma	0.00178	0.00225	CcSEcCtD
Arformoterol—Oedema—Temozolomide—melanoma	0.00178	0.00225	CcSEcCtD
Arformoterol—Infection—Temozolomide—melanoma	0.00177	0.00224	CcSEcCtD
Arformoterol—Nervous system disorder—Temozolomide—melanoma	0.00175	0.00221	CcSEcCtD
Arformoterol—Feeling abnormal—Bleomycin—melanoma	0.00174	0.0022	CcSEcCtD
Arformoterol—Skin disorder—Temozolomide—melanoma	0.00173	0.00219	CcSEcCtD
Arformoterol—Hypotension—Carmustine—melanoma	0.00173	0.00218	CcSEcCtD
Arformoterol—Fatigue—Dactinomycin—melanoma	0.0017	0.00215	CcSEcCtD
Arformoterol—Pain—Dactinomycin—melanoma	0.00169	0.00213	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Carmustine—melanoma	0.00168	0.00212	CcSEcCtD
Arformoterol—Urticaria—Bleomycin—melanoma	0.00168	0.00212	CcSEcCtD
Arformoterol—Rhinitis—Docetaxel—melanoma	0.00167	0.00211	CcSEcCtD
Arformoterol—Body temperature increased—Bleomycin—melanoma	0.00167	0.00211	CcSEcCtD
Arformoterol—Insomnia—Carmustine—melanoma	0.00167	0.00211	CcSEcCtD
Arformoterol—Pharyngitis—Docetaxel—melanoma	0.00166	0.00209	CcSEcCtD
Arformoterol—Urinary tract disorder—Docetaxel—melanoma	0.00165	0.00208	CcSEcCtD
Arformoterol—Dyspnoea—Carmustine—melanoma	0.00165	0.00208	CcSEcCtD
Arformoterol—Oedema peripheral—Docetaxel—melanoma	0.00165	0.00208	CcSEcCtD
Arformoterol—Somnolence—Carmustine—melanoma	0.00164	0.00207	CcSEcCtD
Arformoterol—Connective tissue disorder—Docetaxel—melanoma	0.00164	0.00207	CcSEcCtD
Arformoterol—Urethral disorder—Docetaxel—melanoma	0.00164	0.00207	CcSEcCtD
Arformoterol—Feeling abnormal—Dactinomycin—melanoma	0.00163	0.00205	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Temozolomide—melanoma	0.00163	0.00205	CcSEcCtD
Arformoterol—Insomnia—Temozolomide—melanoma	0.00161	0.00204	CcSEcCtD
Arformoterol—Gastrointestinal pain—Dactinomycin—melanoma	0.00161	0.00204	CcSEcCtD
Arformoterol—Visual impairment—Docetaxel—melanoma	0.00161	0.00203	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Carmustine—melanoma	0.00159	0.00201	CcSEcCtD
Arformoterol—Dyspnoea—Temozolomide—melanoma	0.00159	0.00201	CcSEcCtD
Arformoterol—Somnolence—Temozolomide—melanoma	0.00159	0.002	CcSEcCtD
Arformoterol—Constipation—Carmustine—melanoma	0.00158	0.00199	CcSEcCtD
Arformoterol—Pain—Carmustine—melanoma	0.00158	0.00199	CcSEcCtD
Arformoterol—Dyspepsia—Temozolomide—melanoma	0.00157	0.00198	CcSEcCtD
Arformoterol—Abdominal pain—Dactinomycin—melanoma	0.00156	0.00197	CcSEcCtD
Arformoterol—Body temperature increased—Dactinomycin—melanoma	0.00156	0.00197	CcSEcCtD
Arformoterol—Hypersensitivity—Bleomycin—melanoma	0.00156	0.00197	CcSEcCtD
Arformoterol—Cardiac disorder—Docetaxel—melanoma	0.00155	0.00196	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Temozolomide—melanoma	0.00154	0.00194	CcSEcCtD
Arformoterol—Fatigue—Temozolomide—melanoma	0.00154	0.00194	CcSEcCtD
Arformoterol—Pain—Temozolomide—melanoma	0.00153	0.00193	CcSEcCtD
Arformoterol—Constipation—Temozolomide—melanoma	0.00153	0.00193	CcSEcCtD
Arformoterol—Feeling abnormal—Carmustine—melanoma	0.00152	0.00192	CcSEcCtD
Arformoterol—Asthenia—Bleomycin—melanoma	0.00152	0.00191	CcSEcCtD
Arformoterol—Gastrointestinal pain—Carmustine—melanoma	0.00151	0.00191	CcSEcCtD
Arformoterol—Immune system disorder—Docetaxel—melanoma	0.00151	0.0019	CcSEcCtD
Arformoterol—Mediastinal disorder—Docetaxel—melanoma	0.00151	0.0019	CcSEcCtD
Arformoterol—Pruritus—Bleomycin—melanoma	0.0015	0.00189	CcSEcCtD
Arformoterol—Arrhythmia—Docetaxel—melanoma	0.00149	0.00188	CcSEcCtD
Arformoterol—Feeling abnormal—Temozolomide—melanoma	0.00147	0.00186	CcSEcCtD
Arformoterol—Mental disorder—Docetaxel—melanoma	0.00146	0.00185	CcSEcCtD
Arformoterol—Abdominal pain—Carmustine—melanoma	0.00146	0.00184	CcSEcCtD
Arformoterol—Body temperature increased—Carmustine—melanoma	0.00146	0.00184	CcSEcCtD
Arformoterol—Gastrointestinal pain—Temozolomide—melanoma	0.00146	0.00184	CcSEcCtD
Arformoterol—Malnutrition—Docetaxel—melanoma	0.00145	0.00183	CcSEcCtD
Arformoterol—Hypersensitivity—Dactinomycin—melanoma	0.00145	0.00183	CcSEcCtD
Arformoterol—Dysgeusia—Docetaxel—melanoma	0.00142	0.0018	CcSEcCtD
Arformoterol—Urticaria—Temozolomide—melanoma	0.00142	0.00179	CcSEcCtD
Arformoterol—Asthenia—Dactinomycin—melanoma	0.00142	0.00179	CcSEcCtD
Arformoterol—Abdominal pain—Temozolomide—melanoma	0.00141	0.00178	CcSEcCtD
Arformoterol—Body temperature increased—Temozolomide—melanoma	0.00141	0.00178	CcSEcCtD
Arformoterol—Back pain—Docetaxel—melanoma	0.00141	0.00177	CcSEcCtD
Arformoterol—Muscle spasms—Docetaxel—melanoma	0.0014	0.00176	CcSEcCtD
Arformoterol—Hypersensitivity—Carmustine—melanoma	0.00136	0.00172	CcSEcCtD
Arformoterol—Diarrhoea—Dactinomycin—melanoma	0.00135	0.0017	CcSEcCtD
Arformoterol—Vomiting—Bleomycin—melanoma	0.00134	0.0017	CcSEcCtD
Arformoterol—Rash—Bleomycin—melanoma	0.00133	0.00168	CcSEcCtD
Arformoterol—Dermatitis—Bleomycin—melanoma	0.00133	0.00168	CcSEcCtD
Arformoterol—Asthenia—Carmustine—melanoma	0.00132	0.00167	CcSEcCtD
Arformoterol—Hypersensitivity—Temozolomide—melanoma	0.00131	0.00166	CcSEcCtD
Arformoterol—Palpitations—Docetaxel—melanoma	0.00128	0.00162	CcSEcCtD
Arformoterol—Asthenia—Temozolomide—melanoma	0.00128	0.00162	CcSEcCtD
Arformoterol—Cough—Docetaxel—melanoma	0.00127	0.0016	CcSEcCtD
Arformoterol—Diarrhoea—Carmustine—melanoma	0.00126	0.00159	CcSEcCtD
Arformoterol—Pruritus—Temozolomide—melanoma	0.00126	0.00159	CcSEcCtD
Arformoterol—Nausea—Bleomycin—melanoma	0.00126	0.00159	CcSEcCtD
Arformoterol—Hypertension—Docetaxel—melanoma	0.00126	0.00158	CcSEcCtD
Arformoterol—Vomiting—Dactinomycin—melanoma	0.00125	0.00158	CcSEcCtD
Arformoterol—Rash—Dactinomycin—melanoma	0.00124	0.00157	CcSEcCtD
Arformoterol—Chest pain—Docetaxel—melanoma	0.00124	0.00156	CcSEcCtD
Arformoterol—Myalgia—Docetaxel—melanoma	0.00124	0.00156	CcSEcCtD
Arformoterol—Arthralgia—Docetaxel—melanoma	0.00124	0.00156	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00123	0.00155	CcSEcCtD
Arformoterol—Dizziness—Carmustine—melanoma	0.00122	0.00154	CcSEcCtD
Arformoterol—Diarrhoea—Temozolomide—melanoma	0.00122	0.00154	CcSEcCtD
Arformoterol—Dry mouth—Docetaxel—melanoma	0.00121	0.00153	CcSEcCtD
Arformoterol—Oedema—Docetaxel—melanoma	0.00119	0.0015	CcSEcCtD
Arformoterol—Anaphylactic shock—Docetaxel—melanoma	0.00119	0.0015	CcSEcCtD
Arformoterol—Dizziness—Temozolomide—melanoma	0.00118	0.00149	CcSEcCtD
Arformoterol—Infection—Docetaxel—melanoma	0.00118	0.00149	CcSEcCtD
Arformoterol—Vomiting—Carmustine—melanoma	0.00117	0.00148	CcSEcCtD
Arformoterol—Nausea—Dactinomycin—melanoma	0.00117	0.00148	CcSEcCtD
Arformoterol—Rash—Carmustine—melanoma	0.00116	0.00147	CcSEcCtD
Arformoterol—Nervous system disorder—Docetaxel—melanoma	0.00116	0.00147	CcSEcCtD
Arformoterol—Dermatitis—Carmustine—melanoma	0.00116	0.00147	CcSEcCtD
Arformoterol—Tachycardia—Docetaxel—melanoma	0.00116	0.00146	CcSEcCtD
Arformoterol—Headache—Carmustine—melanoma	0.00116	0.00146	CcSEcCtD
Arformoterol—Skin disorder—Docetaxel—melanoma	0.00115	0.00145	CcSEcCtD
Arformoterol—Vomiting—Temozolomide—melanoma	0.00113	0.00143	CcSEcCtD
Arformoterol—Rash—Temozolomide—melanoma	0.00112	0.00142	CcSEcCtD
Arformoterol—Dermatitis—Temozolomide—melanoma	0.00112	0.00142	CcSEcCtD
Arformoterol—Headache—Temozolomide—melanoma	0.00112	0.00141	CcSEcCtD
Arformoterol—Hypotension—Docetaxel—melanoma	0.00111	0.0014	CcSEcCtD
Arformoterol—Nausea—Carmustine—melanoma	0.0011	0.00138	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Docetaxel—melanoma	0.00108	0.00136	CcSEcCtD
Arformoterol—Insomnia—Docetaxel—melanoma	0.00107	0.00135	CcSEcCtD
Arformoterol—Nausea—Temozolomide—melanoma	0.00106	0.00134	CcSEcCtD
Arformoterol—Dyspnoea—Docetaxel—melanoma	0.00106	0.00133	CcSEcCtD
Arformoterol—Somnolence—Docetaxel—melanoma	0.00105	0.00133	CcSEcCtD
Arformoterol—Dyspepsia—Docetaxel—melanoma	0.00104	0.00132	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Docetaxel—melanoma	0.00102	0.00129	CcSEcCtD
Arformoterol—Fatigue—Docetaxel—melanoma	0.00102	0.00129	CcSEcCtD
Arformoterol—Pain—Docetaxel—melanoma	0.00101	0.00128	CcSEcCtD
Arformoterol—Constipation—Docetaxel—melanoma	0.00101	0.00128	CcSEcCtD
Arformoterol—Feeling abnormal—Docetaxel—melanoma	0.000978	0.00123	CcSEcCtD
Arformoterol—Gastrointestinal pain—Docetaxel—melanoma	0.00097	0.00122	CcSEcCtD
Arformoterol—Body temperature increased—Docetaxel—melanoma	0.000938	0.00118	CcSEcCtD
Arformoterol—Abdominal pain—Docetaxel—melanoma	0.000938	0.00118	CcSEcCtD
Arformoterol—Hypersensitivity—Docetaxel—melanoma	0.000874	0.0011	CcSEcCtD
Arformoterol—Asthenia—Docetaxel—melanoma	0.000851	0.00107	CcSEcCtD
Arformoterol—Pruritus—Docetaxel—melanoma	0.000839	0.00106	CcSEcCtD
Arformoterol—Diarrhoea—Docetaxel—melanoma	0.000812	0.00102	CcSEcCtD
Arformoterol—Dizziness—Docetaxel—melanoma	0.000785	0.00099	CcSEcCtD
Arformoterol—Vomiting—Docetaxel—melanoma	0.000754	0.000952	CcSEcCtD
Arformoterol—Rash—Docetaxel—melanoma	0.000748	0.000944	CcSEcCtD
Arformoterol—Dermatitis—Docetaxel—melanoma	0.000747	0.000943	CcSEcCtD
Arformoterol—Headache—Docetaxel—melanoma	0.000743	0.000938	CcSEcCtD
Arformoterol—Nausea—Docetaxel—melanoma	0.000705	0.000889	CcSEcCtD
Arformoterol—ADRB1—Signaling Pathways—SYK—melanoma	6.54e-05	0.000331	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—PIK3CD—melanoma	6.49e-05	0.000328	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—AKT3—melanoma	6.42e-05	0.000325	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NGFR—melanoma	6.42e-05	0.000325	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ITGAV—melanoma	6.42e-05	0.000325	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—SYK—melanoma	6.4e-05	0.000324	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—PIK3CD—melanoma	6.35e-05	0.000321	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ITGAV—melanoma	6.28e-05	0.000318	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—AKT3—melanoma	6.28e-05	0.000318	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NGFR—melanoma	6.28e-05	0.000318	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PLA2G6—melanoma	6.13e-05	0.00031	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PLA2G6—melanoma	6.07e-05	0.000307	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—VCAN—melanoma	5.98e-05	0.000303	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—SOCS1—melanoma	5.95e-05	0.000301	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—MAP2K1—melanoma	5.93e-05	0.0003	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—S100B—melanoma	5.93e-05	0.0003	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—PIK3CD—melanoma	5.89e-05	0.000298	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—SOCS1—melanoma	5.82e-05	0.000294	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—MAP2K1—melanoma	5.8e-05	0.000294	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—S100B—melanoma	5.8e-05	0.000293	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—PIK3CD—melanoma	5.76e-05	0.000292	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—ABCB1—melanoma	5.74e-05	0.00029	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ERBB4—melanoma	5.67e-05	0.000287	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	5.66e-05	0.000286	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—PIK3CB—melanoma	5.66e-05	0.000286	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CDKN2B—melanoma	5.62e-05	0.000284	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ERBB4—melanoma	5.55e-05	0.000281	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—PIK3CB—melanoma	5.53e-05	0.00028	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—VCAN—melanoma	5.5e-05	0.000278	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CDKN2B—melanoma	5.5e-05	0.000278	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—melanoma	5.47e-05	0.000276	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—VCAN—melanoma	5.46e-05	0.000276	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CD86—melanoma	5.44e-05	0.000275	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—CXCL8—melanoma	5.44e-05	0.000275	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—EDN1—melanoma	5.4e-05	0.000273	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CD86—melanoma	5.32e-05	0.000269	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—CXCL8—melanoma	5.32e-05	0.000269	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PRKCA—melanoma	5.28e-05	0.000267	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—EDN1—melanoma	5.28e-05	0.000267	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CSF2—melanoma	5.27e-05	0.000267	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—FGF1—melanoma	5.27e-05	0.000267	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—ERCC2—melanoma	5.24e-05	0.000265	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—IL2—melanoma	5.19e-05	0.000263	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	5.16e-05	0.000261	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—E2F1—melanoma	5.16e-05	0.000261	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CSF2—melanoma	5.16e-05	0.000261	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—FGF1—melanoma	5.16e-05	0.000261	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—PIK3CB—melanoma	5.14e-05	0.00026	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PDGFRA—melanoma	5.11e-05	0.000258	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—IL2—melanoma	5.08e-05	0.000257	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ITGB3—melanoma	5.06e-05	0.000256	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PRKCA—melanoma	5.06e-05	0.000256	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP17A1—melanoma	5.05e-05	0.000255	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—E2F1—melanoma	5.05e-05	0.000255	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—PIK3CB—melanoma	5.02e-05	0.000254	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PDGFRA—melanoma	5e-05	0.000253	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—melanoma	4.98e-05	0.000252	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	4.98e-05	0.000252	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—SPP1—melanoma	4.96e-05	0.000251	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ITGB3—melanoma	4.95e-05	0.00025	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PRKCA—melanoma	4.95e-05	0.00025	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MAP2K2—melanoma	4.94e-05	0.00025	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—CXCL8—melanoma	4.94e-05	0.00025	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—melanoma	4.92e-05	0.000249	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—SPP1—melanoma	4.85e-05	0.000245	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MAP2K2—melanoma	4.83e-05	0.000245	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—CXCL8—melanoma	4.83e-05	0.000244	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GNA11—melanoma	4.77e-05	0.000241	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—IL2—melanoma	4.72e-05	0.000239	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TERT—melanoma	4.7e-05	0.000238	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—RAC1—melanoma	4.69e-05	0.000237	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—FASN—melanoma	4.67e-05	0.000236	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP17A1—melanoma	4.64e-05	0.000235	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—IL2—melanoma	4.61e-05	0.000233	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP17A1—melanoma	4.6e-05	0.000233	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TERT—melanoma	4.6e-05	0.000233	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—SLC5A5—melanoma	4.59e-05	0.000232	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—RAC1—melanoma	4.59e-05	0.000232	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	4.54e-05	0.00023	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HIF1A—melanoma	4.5e-05	0.000227	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—melanoma	4.48e-05	0.000227	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CD44—melanoma	4.43e-05	0.000224	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GNAQ—melanoma	4.43e-05	0.000224	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HIF1A—melanoma	4.4e-05	0.000222	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GNA11—melanoma	4.39e-05	0.000222	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GNA11—melanoma	4.35e-05	0.00022	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	4.34e-05	0.00022	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—melanoma	4.3e-05	0.000218	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KDR—melanoma	4.3e-05	0.000217	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—FASN—melanoma	4.29e-05	0.000217	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—FASN—melanoma	4.25e-05	0.000215	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP1B1—melanoma	4.25e-05	0.000215	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—SLC5A5—melanoma	4.22e-05	0.000213	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KDR—melanoma	4.21e-05	0.000213	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—SLC5A5—melanoma	4.18e-05	0.000212	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—FN1—melanoma	4.14e-05	0.000209	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CG—melanoma	4.14e-05	0.000209	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CD44—melanoma	4.08e-05	0.000206	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GNAQ—melanoma	4.08e-05	0.000206	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NOTCH1—melanoma	4.05e-05	0.000205	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—FN1—melanoma	4.05e-05	0.000205	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GNAQ—melanoma	4.04e-05	0.000204	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CD44—melanoma	4.04e-05	0.000204	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PPARG—melanoma	3.99e-05	0.000202	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CD80—melanoma	3.97e-05	0.000201	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NOTCH1—melanoma	3.96e-05	0.0002	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CG—melanoma	3.96e-05	0.0002	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KIT—melanoma	3.96e-05	0.0002	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—APC—melanoma	3.96e-05	0.0002	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—NRAS—melanoma	3.96e-05	0.0002	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	3.96e-05	0.0002	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	3.92e-05	0.000198	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—EGF—melanoma	3.91e-05	0.000198	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP1B1—melanoma	3.91e-05	0.000198	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CD80—melanoma	3.88e-05	0.000196	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP1B1—melanoma	3.87e-05	0.000196	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CG—melanoma	3.87e-05	0.000196	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KIT—melanoma	3.87e-05	0.000196	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—APC—melanoma	3.87e-05	0.000196	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—NRAS—melanoma	3.87e-05	0.000196	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—EGF—melanoma	3.83e-05	0.000194	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—MAPK3—melanoma	3.79e-05	0.000192	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.75e-05	0.00019	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—BRAF—melanoma	3.72e-05	0.000188	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—MAPK3—melanoma	3.71e-05	0.000188	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—BRAF—melanoma	3.64e-05	0.000184	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CD—melanoma	3.64e-05	0.000184	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IGF1—melanoma	3.63e-05	0.000183	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—MAPK1—melanoma	3.61e-05	0.000183	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—EGFR—melanoma	3.61e-05	0.000182	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—ALB—melanoma	3.59e-05	0.000182	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IGF1—melanoma	3.55e-05	0.000179	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—MAPK1—melanoma	3.53e-05	0.000179	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—EGFR—melanoma	3.53e-05	0.000179	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MAP2K1—melanoma	3.5e-05	0.000177	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ABCB1—melanoma	3.5e-05	0.000177	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CD—melanoma	3.48e-05	0.000176	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—PIK3CA—melanoma	3.45e-05	0.000174	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MAP2K1—melanoma	3.43e-05	0.000173	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.42e-05	0.000173	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—KRAS—melanoma	3.41e-05	0.000172	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CD—melanoma	3.41e-05	0.000172	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—PIK3CA—melanoma	3.37e-05	0.000171	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—KRAS—melanoma	3.33e-05	0.000169	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—FGF2—melanoma	3.33e-05	0.000169	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—FGF2—melanoma	3.26e-05	0.000165	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PRKCA—melanoma	3.22e-05	0.000163	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ABCB1—melanoma	3.22e-05	0.000163	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ERCC2—melanoma	3.19e-05	0.000162	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ABCB1—melanoma	3.19e-05	0.000161	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CB—melanoma	3.17e-05	0.00016	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PTGS2—melanoma	3.14e-05	0.000159	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—PIK3CA—melanoma	3.13e-05	0.000158	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MDM2—melanoma	3.12e-05	0.000158	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ERBB2—melanoma	3.07e-05	0.000156	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—PIK3CA—melanoma	3.06e-05	0.000155	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MDM2—melanoma	3.05e-05	0.000154	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CB—melanoma	3.03e-05	0.000153	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ERBB2—melanoma	3.01e-05	0.000152	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CB—melanoma	2.97e-05	0.00015	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PRKCA—melanoma	2.96e-05	0.00015	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ERCC2—melanoma	2.94e-05	0.000149	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PRKCA—melanoma	2.94e-05	0.000149	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CXCL8—melanoma	2.92e-05	0.000147	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ERCC2—melanoma	2.91e-05	0.000147	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—HRAS—melanoma	2.9e-05	0.000147	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CXCL8—melanoma	2.85e-05	0.000144	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CDKN1B—melanoma	2.85e-05	0.000144	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—HRAS—melanoma	2.83e-05	0.000143	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—AKT1—melanoma	2.82e-05	0.000142	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CASP3—melanoma	2.79e-05	0.000141	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL2—melanoma	2.79e-05	0.000141	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CDKN1B—melanoma	2.79e-05	0.000141	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—IL6—melanoma	2.77e-05	0.00014	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—AKT1—melanoma	2.76e-05	0.000139	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PTEN—melanoma	2.74e-05	0.000139	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CASP3—melanoma	2.73e-05	0.000138	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL2—melanoma	2.73e-05	0.000138	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CCND1—melanoma	2.72e-05	0.000137	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—IL6—melanoma	2.71e-05	0.000137	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CTNNB1—melanoma	2.69e-05	0.000136	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CCND1—melanoma	2.66e-05	0.000134	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.65e-05	0.000134	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MMP9—melanoma	2.64e-05	0.000133	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CTNNB1—melanoma	2.63e-05	0.000133	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CDKN1A—melanoma	2.63e-05	0.000133	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PTEN—melanoma	2.62e-05	0.000133	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NFKB1—melanoma	2.61e-05	0.000132	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MMP9—melanoma	2.58e-05	0.00013	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CDKN1A—melanoma	2.57e-05	0.00013	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PTEN—melanoma	2.57e-05	0.00013	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—AKT1—melanoma	2.56e-05	0.000129	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NFKB1—melanoma	2.55e-05	0.000129	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CG—melanoma	2.52e-05	0.000128	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—AKT1—melanoma	2.5e-05	0.000127	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PPARG—melanoma	2.43e-05	0.000123	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.41e-05	0.000122	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—VEGFA—melanoma	2.37e-05	0.00012	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—STAT3—melanoma	2.35e-05	0.000119	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NRAS—melanoma	2.34e-05	0.000118	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CG—melanoma	2.32e-05	0.000117	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—VEGFA—melanoma	2.32e-05	0.000117	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CG—melanoma	2.3e-05	0.000116	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—STAT3—melanoma	2.29e-05	0.000116	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NRAS—melanoma	2.29e-05	0.000116	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MAPK3—melanoma	2.24e-05	0.000113	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PPARG—melanoma	2.24e-05	0.000113	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PPARG—melanoma	2.22e-05	0.000112	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CD—melanoma	2.22e-05	0.000112	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MAPK3—melanoma	2.19e-05	0.000111	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ALB—melanoma	2.19e-05	0.000111	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MYC—melanoma	2.18e-05	0.00011	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MAPK1—melanoma	2.13e-05	0.000108	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MYC—melanoma	2.13e-05	0.000108	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—EGFR—melanoma	2.13e-05	0.000108	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MAPK1—melanoma	2.09e-05	0.000105	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—EGFR—melanoma	2.08e-05	0.000105	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CD—melanoma	2.04e-05	0.000103	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CD—melanoma	2.02e-05	0.000102	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KRAS—melanoma	2.01e-05	0.000102	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ALB—melanoma	2.01e-05	0.000102	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ALB—melanoma	2e-05	0.000101	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KRAS—melanoma	1.97e-05	9.96e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CB—melanoma	1.93e-05	9.78e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CA—melanoma	1.93e-05	9.77e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PTGS2—melanoma	1.92e-05	9.69e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CA—melanoma	1.85e-05	9.36e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CA—melanoma	1.81e-05	9.15e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TP53—melanoma	1.79e-05	9.05e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CB—melanoma	1.78e-05	8.99e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CB—melanoma	1.76e-05	8.91e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PTGS2—melanoma	1.76e-05	8.91e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TP53—melanoma	1.75e-05	8.85e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PTGS2—melanoma	1.75e-05	8.83e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HRAS—melanoma	1.71e-05	8.66e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HRAS—melanoma	1.67e-05	8.47e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PTEN—melanoma	1.67e-05	8.45e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL6—melanoma	1.64e-05	8.28e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL6—melanoma	1.6e-05	8.1e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—AKT1—melanoma	1.58e-05	7.98e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PTEN—melanoma	1.54e-05	7.77e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PTEN—melanoma	1.52e-05	7.7e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—AKT1—melanoma	1.51e-05	7.64e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—AKT1—melanoma	1.48e-05	7.48e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CA—melanoma	1.18e-05	5.96e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CA—melanoma	1.08e-05	5.48e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CA—melanoma	1.07e-05	5.43e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—AKT1—melanoma	9.63e-06	4.87e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—AKT1—melanoma	8.85e-06	4.48e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—AKT1—melanoma	8.78e-06	4.44e-05	CbGpPWpGaD
